CA2827029C - Tripeptide compositions and methods - Google Patents

Tripeptide compositions and methods Download PDF

Info

Publication number
CA2827029C
CA2827029C CA2827029A CA2827029A CA2827029C CA 2827029 C CA2827029 C CA 2827029C CA 2827029 A CA2827029 A CA 2827029A CA 2827029 A CA2827029 A CA 2827029A CA 2827029 C CA2827029 C CA 2827029C
Authority
CA
Canada
Prior art keywords
peptide
amino acid
acid sequence
pharmaceutically acceptable
gll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2827029A
Other languages
English (en)
French (fr)
Other versions
CA2827029A1 (en
Inventor
Yuqing E. Chen
Changyong XUE
Jifeng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CA2827029A1 publication Critical patent/CA2827029A1/en
Application granted granted Critical
Publication of CA2827029C publication Critical patent/CA2827029C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2827029A 2011-02-11 2012-02-10 Tripeptide compositions and methods Active CA2827029C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441748P 2011-02-11 2011-02-11
US61/441,748 2011-02-11
PCT/US2012/024684 WO2012109561A2 (en) 2011-02-11 2012-02-10 Peptide compositions and methods for treating patients

Publications (2)

Publication Number Publication Date
CA2827029A1 CA2827029A1 (en) 2012-08-16
CA2827029C true CA2827029C (en) 2019-07-02

Family

ID=45852697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827029A Active CA2827029C (en) 2011-02-11 2012-02-10 Tripeptide compositions and methods

Country Status (11)

Country Link
US (2) US8664177B2 (enExample)
EP (1) EP2683393B1 (enExample)
JP (3) JP5946473B2 (enExample)
CN (2) CN105617351A (enExample)
AU (1) AU2012214283B2 (enExample)
CA (1) CA2827029C (enExample)
DK (1) DK2683393T3 (enExample)
ES (1) ES2673672T3 (enExample)
HU (1) HUE038787T2 (enExample)
MX (1) MX353301B (enExample)
WO (1) WO2012109561A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2683393B1 (en) 2011-02-11 2018-04-11 The Regents of The University of Michigan Tripeptide compositions and their use for treatment of diabetes
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US20180074053A1 (en) * 2015-04-03 2018-03-15 Zhongmin Ma Treatment of diabetes using agonists of the mas-related gpcr d
KR101909052B1 (ko) * 2017-02-09 2018-10-17 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
JP7068942B2 (ja) * 2018-06-25 2022-05-17 サンスター株式会社 トリペプチド含有組成物
KR20210043588A (ko) * 2018-08-10 2021-04-21 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
CA3190437A1 (en) * 2020-08-18 2022-02-24 The Regents Of The Universtiy Of Michigan N-acyl amino acid products and uses
CN115252758A (zh) * 2022-08-16 2022-11-01 中国科学院南海海洋研究所 线性小分子肽类似物在制备抗肥胖和降糖药物中应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL275394A (enExample) 1961-02-28
AU426743B2 (en) 1967-09-21 1972-07-21 MONASH UNIVERSITY, and ICI AUSTRALIA LIMITED Processes forthe production of peptides and proteins
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
JPH04149139A (ja) * 1990-10-12 1992-05-22 Nippon Steel Corp 血糖降下剤
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6069129A (en) * 1998-03-13 2000-05-30 Mrs, Llc Elastin derived composition and method of using same
WO2000068695A2 (en) 1999-05-12 2000-11-16 Univ Oklahoma State Reagent and process for peptide/protein differentiation using circular dichroism detection
AU2001275018B2 (en) 2000-05-30 2008-04-03 Connective Tissue Imagineering Llc Composition and method for enhancing elasticity of tissue
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
WO2002020769A1 (en) 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
CA2421200A1 (en) 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Adenoviral targeting and manipulation of immune system response using targeting peptides
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
FI114710B (fi) * 2001-03-12 2004-12-15 Ctt Cancer Targeting Tech Oy Leukosyytti-integriinien uusia peptidiligandeja
EP1497314A4 (en) 2001-09-07 2007-10-10 Univ Texas COMPOSITIONS AND METHODS OF USE ON PEPTIDES AGAINST PLACENTA AND FAT FABRICS
WO2003024995A1 (en) * 2001-09-19 2003-03-27 Tripep Ab Molecules that block viral infectivity and methods of use thereof
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
JP2007522246A (ja) 2004-02-12 2007-08-09 ネクター セラピューティクス インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法
WO2005115457A2 (en) 2004-05-10 2005-12-08 University Of Utah Research Foundation Combined active and passive targeting of biologically active agents
US20090221505A1 (en) * 2004-11-16 2009-09-03 Mikhail Kolonin Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
WO2006108211A1 (en) 2005-02-25 2006-10-19 The Murdoch Childrens Research Institute Fragments of von willebrand factor a-related protein
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
GB0601950D0 (en) 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
EP2047848A4 (en) * 2006-07-05 2010-06-09 Univ Tokyo METHOD FOR THE TREATMENT OF GENETIC DISEASES BASED ON A NONSENSE MUTATION
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
CZ298945B6 (cs) 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
WO2009026614A1 (en) * 2007-08-24 2009-03-05 Dia-B Tech Limited Hypoglycaemic tripeptide and methods of use thereof
KR100947547B1 (ko) * 2009-07-23 2010-03-12 월드웨이(주) 실크 펩타이드를 유효성분으로 하는 당뇨 치료 또는 예방용 조성물
EP2683393B1 (en) 2011-02-11 2018-04-11 The Regents of The University of Michigan Tripeptide compositions and their use for treatment of diabetes

Also Published As

Publication number Publication date
CA2827029A1 (en) 2012-08-16
JP2018131446A (ja) 2018-08-23
WO2012109561A3 (en) 2013-01-17
JP5946473B2 (ja) 2016-07-06
JP2016179992A (ja) 2016-10-13
JP2014506579A (ja) 2014-03-17
MX2013009223A (es) 2014-01-23
NZ719672A (en) 2018-12-21
JP6412897B2 (ja) 2018-10-24
AU2012214283B2 (en) 2016-01-28
CN103458911A (zh) 2013-12-18
WO2012109561A2 (en) 2012-08-16
US8664177B2 (en) 2014-03-04
ES2673672T3 (es) 2018-06-25
US20140148382A1 (en) 2014-05-29
EP2683393B1 (en) 2018-04-11
AU2012214283A1 (en) 2013-08-29
CN105617351A (zh) 2016-06-01
NZ614080A (en) 2016-05-27
DK2683393T3 (en) 2018-07-23
CN103458911B (zh) 2016-02-24
US9062093B2 (en) 2015-06-23
EP2683393A2 (en) 2014-01-15
HUE038787T2 (hu) 2018-11-28
MX353301B (es) 2018-01-08
US20120208748A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
CA2827029C (en) Tripeptide compositions and methods
US5418218A (en) Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
KR20150046039A (ko) 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제
JP2001500893A (ja) インスリンｃ―ペプチド
NZ541747A (en) Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
JP5985028B2 (ja) 血圧降下剤
US20210401880A1 (en) Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active Ingredient
US20200038478A1 (en) Polypeptide and composition thereof for treating diseases of metabolic system
HK1193563A (en) Tripeptide compositions and their use for treatment of diabetes
HK1193563B (en) Tripeptide compositions and their use for treatment of diabetes
US8476221B2 (en) Methods and compositions for the treatment of metabolic disorders
NZ614080B2 (en) Tripeptide compositions and methods for treatment of diabetes
NZ719672B2 (en) Tripeptide compositions and methods for treatment of diabetes
US20070049535A1 (en) Preventive/remedy for diabetic complications using oligopeptide
Adam et al. O-33: Omapatrilat (OMA) a vasopeptidase inhibitor prevents mortality and cardiovascular injury in salt sensitive hypertension in addition to but independent of blood pressure
Lisy et al. O-35: Blood pressure lowering, renin suppressing and natriuretic properties of a new designer peptide BD-NP

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170209